hotspot -WSS

hotspot

author：focus 2025-10-02 20:06:28 - browse：67

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Is there really a nursing shortage in the U.S.?

Wikipedia

WSS

Industry veterans launch new biotech VC with $310M

Industry veterans launch new biotech VC with $310M

Robert F. Kennedy is pitching centrism on health, even on abortion

STAT Summit: Ending the crisis of Black deaths in the U.S.

Results on Novartis prostate cancer therapy could expand its use

Smaller biotechs seek to piggyback on weight loss drug boom

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Malaria cases in Florida and Texas: Here’s what you need to know

KalVista pill reduced swelling 'attacks' caused by genetic disease

Guidelines to prevent youth baseball injuries need more muscle

What we’ve learned from the Aduhelm mess

Sports medicine is finally prioritizing gender equality

What should King Charles tell the public about his cancer?

Bright Health sells Medicare Advantage business to Molina

STAT Summit: The economic case for universal basic health care

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: How researchers deal with rejection

leisure time

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Is there really a nursing shortage in the U.S.?

STAT Readout Newsletter: Biotech news today

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Roche drug slashes death risk in early

Private equity deals in Medicare Advantage declines

Wikipedia

explore

hotspot

hotspot